Thermo Fisher Scientific Inc. (0R0H.L)
USD 428.58
(1.97%)
USD 428.58
(1.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.85 Billion USD | -12.81% |
| 2022 | 8.39 Billion USD | -16.3% |
| 2021 | 10.02 Billion USD | 28.66% |
| 2020 | 7.79 Billion USD | 69.66% |
| 2019 | 4.59 Billion USD | 21.44% |
| 2018 | 3.78 Billion USD | 27.46% |
| 2017 | 2.96 Billion USD | 21.18% |
| 2016 | 2.44 Billion USD | 4.84% |
| 2015 | 2.33 Billion USD | -6.66% |
| 2014 | 2.5 Billion USD | 55.5% |
| 2013 | 1.6 Billion USD | 8.6% |
| 2012 | 1.48 Billion USD | 19.03% |
| 2011 | 1.24 Billion USD | -1.56% |
| 2010 | 1.26 Billion USD | 20.59% |
| 2009 | 1.04 Billion USD | -14.68% |
| 2008 | 1.22 Billion USD | 26.17% |
| 2007 | 974.4 Million USD | 302.71% |
| 2006 | 241.95 Million USD | -8.17% |
| 2005 | 263.48 Million USD | 10.94% |
| 2004 | 237.51 Million USD | 28.54% |
| 2003 | 184.77 Million USD | 18.86% |
| 2002 | 155.45 Million USD | 354.51% |
| 2001 | 34.2 Million USD | -82.74% |
| 2000 | 198.16 Million USD | -20.29% |
| 1999 | 248.6 Million USD | -33.85% |
| 1998 | 375.8 Million USD | -7.67% |
| 1997 | 407 Million USD | 43.21% |
| 1996 | 284.2 Million USD | 14.92% |
| 1995 | 247.3 Million USD | 37.54% |
| 1994 | 179.8 Million USD | 45.47% |
| 1993 | 123.6 Million USD | 80.97% |
| 1992 | 68.3 Million USD | 78.33% |
| 1991 | 38.3 Million USD | 7.58% |
| 1990 | 35.6 Million USD | 100.0% |
| 1989 | 17.8 Million USD | -7.29% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.72 Billion USD | -7.23% |
| 2024 Q3 | 1.83 Billion USD | 4.55% |
| 2024 Q2 | 1.75 Billion USD | 2.21% |
| 2023 Q2 | 1.57 Billion USD | 0.96% |
| 2023 Q3 | 1.86 Billion USD | 18.12% |
| 2023 Q4 | 1.85 Billion USD | -0.54% |
| 2023 FY | 7.31 Billion USD | -12.81% |
| 2023 Q1 | 1.56 Billion USD | -16.01% |
| 2022 Q4 | 1.86 Billion USD | 8.83% |
| 2022 Q1 | 2.82 Billion USD | 11.15% |
| 2022 Q2 | 2 Billion USD | -29.07% |
| 2022 FY | 8.39 Billion USD | -16.3% |
| 2022 Q3 | 1.71 Billion USD | -14.54% |
| 2021 FY | 10.02 Billion USD | 28.66% |
| 2021 Q1 | 3.04 Billion USD | -0.72% |
| 2021 Q2 | 2.16 Billion USD | -29.06% |
| 2021 Q3 | 2.27 Billion USD | 5.32% |
| 2021 Q4 | 2.53 Billion USD | 11.41% |
| 2020 Q1 | 906 Million USD | -26.46% |
| 2020 Q4 | 3.07 Billion USD | 26.59% |
| 2020 Q2 | 1.39 Billion USD | 53.53% |
| 2020 FY | 7.79 Billion USD | 69.66% |
| 2020 Q3 | 2.42 Billion USD | 74.41% |
| 2019 Q1 | 920 Million USD | -19.86% |
| 2019 Q2 | 1.49 Billion USD | 62.61% |
| 2019 Q3 | 946 Million USD | -36.76% |
| 2019 Q4 | 1.23 Billion USD | 30.23% |
| 2019 FY | 4.59 Billion USD | 21.44% |
| 2018 Q1 | 786 Million USD | -17.95% |
| 2018 Q4 | 1.14 Billion USD | 25.88% |
| 2018 FY | 3.78 Billion USD | 27.46% |
| 2018 Q3 | 912 Million USD | -2.67% |
| 2018 Q2 | 937 Million USD | 19.21% |
| 2017 Q3 | 636.2 Million USD | -15.34% |
| 2017 Q1 | 622.4 Million USD | -17.3% |
| 2017 Q2 | 751.5 Million USD | 20.74% |
| 2017 Q4 | 958 Million USD | 50.58% |
| 2017 FY | 2.96 Billion USD | 21.18% |
| 2016 FY | 2.44 Billion USD | 4.84% |
| 2016 Q1 | 517.9 Million USD | -24.96% |
| 2016 Q3 | 541.1 Million USD | -15.13% |
| 2016 Q4 | 752.6 Million USD | 39.09% |
| 2016 Q2 | 637.6 Million USD | 23.11% |
| 2015 FY | 2.33 Billion USD | -6.66% |
| 2015 Q1 | 487.3 Million USD | -23.75% |
| 2015 Q2 | 595.8 Million USD | 22.27% |
| 2015 Q3 | 562.9 Million USD | -5.52% |
| 2015 Q4 | 690.2 Million USD | 22.62% |
| 2014 Q4 | 639.1 Million USD | -0.19% |
| 2014 Q1 | 875.5 Million USD | 92.42% |
| 2014 Q2 | 348.1 Million USD | -60.24% |
| 2014 Q3 | 640.3 Million USD | 83.94% |
| 2014 FY | 2.5 Billion USD | 55.5% |
| 2013 Q2 | 375.4 Million USD | -3.02% |
| 2013 Q1 | 387.1 Million USD | -3.37% |
| 2013 FY | 1.6 Billion USD | 8.6% |
| 2013 Q4 | 455 Million USD | 16.04% |
| 2013 Q3 | 392.1 Million USD | 4.45% |
| 2012 Q3 | 352.2 Million USD | -4.24% |
| 2012 Q2 | 367.8 Million USD | 3.63% |
| 2012 Q1 | 354.9 Million USD | 3.5% |
| 2012 FY | 1.48 Billion USD | 19.03% |
| 2012 Q4 | 400.6 Million USD | 13.74% |
| 2011 Q4 | 342.9 Million USD | 8.86% |
| 2011 Q1 | 321.5 Million USD | -5.8% |
| 2011 Q2 | 265.8 Million USD | -17.33% |
| 2011 Q3 | 315 Million USD | 18.51% |
| 2011 FY | 1.24 Billion USD | -1.56% |
| 2010 FY | 1.26 Billion USD | 20.59% |
| 2010 Q4 | 341.3 Million USD | 7.12% |
| 2010 Q3 | 318.6 Million USD | 2.12% |
| 2010 Q2 | 312 Million USD | 6.48% |
| 2010 Q1 | 293 Million USD | -9.65% |
| 2009 Q4 | 324.3 Million USD | 17.71% |
| 2009 FY | 1.04 Billion USD | -14.68% |
| 2009 Q2 | 259 Million USD | 36.24% |
| 2009 Q3 | 275.5 Million USD | 6.37% |
| 2009 Q1 | 190.1 Million USD | -41.05% |
| 2008 Q4 | 322.5 Million USD | 12.64% |
| 2008 FY | 1.22 Billion USD | 26.17% |
| 2008 Q1 | 290.4 Million USD | 1.89% |
| 2008 Q2 | 330.2 Million USD | 13.71% |
| 2008 Q3 | 286.3 Million USD | -13.29% |
| 2007 Q1 | 192.4 Million USD | 617.11% |
| 2007 Q4 | 285 Million USD | 12.2% |
| 2007 FY | 974.4 Million USD | 302.71% |
| 2007 Q2 | 243 Million USD | 26.3% |
| 2007 Q3 | 254 Million USD | 4.53% |
| 2006 FY | 241.95 Million USD | -8.17% |
| 2006 Q1 | 67.84 Million USD | -23.33% |
| 2006 Q3 | 75.11 Million USD | 4.07% |
| 2006 Q4 | 26.83 Million USD | -64.28% |
| 2006 Q2 | 72.17 Million USD | 6.38% |
| 2005 Q4 | 88.48 Million USD | 42.47% |
| 2005 FY | 263.48 Million USD | 10.94% |
| 2005 Q3 | 62.11 Million USD | 16.92% |
| 2005 Q2 | 53.12 Million USD | -10.98% |
| 2005 Q1 | 59.67 Million USD | -9.65% |
| 2004 Q3 | 59.62 Million USD | 1.1% |
| 2004 Q1 | 57.88 Million USD | 5.6% |
| 2004 FY | 237.51 Million USD | 28.54% |
| 2004 Q4 | 66.04 Million USD | 10.78% |
| 2004 Q2 | 58.97 Million USD | 1.87% |
| 2003 Q2 | 48.28 Million USD | 22.87% |
| 2003 Q3 | 42.38 Million USD | -12.22% |
| 2003 Q4 | 54.81 Million USD | 29.34% |
| 2003 Q1 | 39.29 Million USD | 1.61% |
| 2003 FY | 184.77 Million USD | 18.86% |
| 2002 FY | 155.45 Million USD | 354.51% |
| 2002 Q3 | 44.87 Million USD | 27.56% |
| 2002 Q2 | 35.17 Million USD | -4.24% |
| 2002 Q1 | 36.73 Million USD | 175.84% |
| 2002 Q4 | 38.67 Million USD | -13.82% |
| 2001 Q4 | -48.43 Million USD | -269.16% |
| 2001 FY | 34.2 Million USD | -82.74% |
| 2001 Q3 | 28.63 Million USD | 102.15% |
| 2001 Q2 | 14.16 Million USD | -64.45% |
| 2001 Q1 | 39.84 Million USD | -12.49% |
| 2000 Q4 | 45.52 Million USD | 4.86% |
| 2000 FY | 198.16 Million USD | -20.29% |
| 2000 Q3 | 43.41 Million USD | -24.62% |
| 2000 Q1 | 51.61 Million USD | 21.74% |
| 2000 Q2 | 57.59 Million USD | 11.59% |
| 1999 Q2 | 55.2 Million USD | -18.46% |
| 1999 FY | 248.6 Million USD | -33.85% |
| 1999 Q1 | 67.7 Million USD | -13.87% |
| 1999 Q4 | 42.4 Million USD | -49.1% |
| 1999 Q3 | 83.3 Million USD | 50.91% |
| 1998 FY | 375.8 Million USD | -7.67% |
| 1998 Q1 | 92.5 Million USD | -23.17% |
| 1998 Q2 | 105.5 Million USD | 14.05% |
| 1998 Q3 | 95.3 Million USD | -9.67% |
| 1998 Q4 | 78.6 Million USD | -17.52% |
| 1997 FY | 407 Million USD | 43.21% |
| 1997 Q4 | 120.4 Million USD | 0.92% |
| 1997 Q3 | 119.3 Million USD | 21.24% |
| 1997 Q2 | 98.4 Million USD | 42.82% |
| 1997 Q1 | 68.9 Million USD | -21.08% |
| 1996 FY | 284.2 Million USD | 14.92% |
| 1996 Q1 | 55.5 Million USD | -24.9% |
| 1996 Q4 | 87.3 Million USD | 11.78% |
| 1996 Q2 | 62.1 Million USD | 11.89% |
| 1996 Q3 | 78.1 Million USD | 25.76% |
| 1995 Q2 | 57.7 Million USD | 21.73% |
| 1995 Q4 | 73.9 Million USD | 8.04% |
| 1995 Q3 | 68.4 Million USD | 18.54% |
| 1995 Q1 | 47.4 Million USD | -11.24% |
| 1995 FY | 247.3 Million USD | 37.54% |
| 1994 Q2 | 42.8 Million USD | 15.99% |
| 1994 Q3 | 46.9 Million USD | 9.58% |
| 1994 Q4 | 53.4 Million USD | 13.86% |
| 1994 FY | 179.8 Million USD | 45.47% |
| 1994 Q1 | 36.9 Million USD | -2.89% |
| 1993 Q2 | 23.5 Million USD | 0.0% |
| 1993 Q4 | 38 Million USD | -4.04% |
| 1993 Q1 | 23.5 Million USD | 26.34% |
| 1993 Q3 | 39.6 Million USD | 68.51% |
| 1993 FY | 123.6 Million USD | 80.97% |
| 1992 Q3 | 24 Million USD | 41.18% |
| 1992 Q4 | 18.6 Million USD | -22.5% |
| 1992 Q1 | 8.7 Million USD | -4.4% |
| 1992 Q2 | 17 Million USD | 95.4% |
| 1992 FY | 68.3 Million USD | 78.33% |
| 1991 Q3 | 9.1 Million USD | -2.15% |
| 1991 Q4 | 9.1 Million USD | 0.0% |
| 1991 Q1 | 9.2 Million USD | -33.81% |
| 1991 FY | 38.3 Million USD | 7.58% |
| 1991 Q2 | 9.3 Million USD | 1.09% |
| 1990 Q3 | 13.5 Million USD | 743.75% |
| 1990 Q4 | 13.9 Million USD | 2.96% |
| 1990 Q1 | 5.8 Million USD | 56.76% |
| 1990 Q2 | 1.6 Million USD | -72.41% |
| 1990 FY | 35.6 Million USD | 100.0% |
| 1989 Q1 | 137.2 Million USD | 141.44% |
| 1989 FY | 17.8 Million USD | -7.29% |
| 1989 Q4 | 3.7 Million USD | 19.35% |
| 1989 Q2 | 150.8 Million USD | 9.91% |
| 1989 Q3 | 3.1 Million USD | -97.94% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| uniQure N.V. | -282.87 Million USD | 2524.78% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 1852.038% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 9432.735% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 2585.091% |
| bluebird bio, Inc. | -244.26 Million USD | 2908.05% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 5745.5% |
| Imunon, Inc. | -21.03 Million USD | 32714.645% |
| Editas Medicine, Inc. | -169.18 Million USD | 4154.238% |
| IQVIA Holdings Inc. | 1.97 Billion USD | -246.94% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -530.839% |
| Myriad Genetics, Inc. | -123.7 Million USD | 5644.867% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -2633.758% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 130276.504% |
| Verastem, Inc. | -92.08 Million USD | 7548.634% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 148.728% |
| Waters Corporation | 817.67 Million USD | -738.841% |
| Biogen Inc. | 1.29 Billion USD | -428.917% |
| Nektar Therapeutics | -137.42 Million USD | 5091.086% |
| Perrigo Company plc | 151.9 Million USD | -4415.471% |
| Dynavax Technologies Corporation | -37.02 Million USD | 18623.82% |
| Illumina, Inc. | -1.06 Billion USD | 741.628% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 15316.084% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 1589.277% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 6300.787% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 15455.856% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -3427.548% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 2603.239% |
| Evolus, Inc. | -49.23 Million USD | 14031.712% |
| Adicet Bio, Inc. | -152.03 Million USD | 4611.372% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 7145.205% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | -69.479% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 4509.146% |
| FibroGen, Inc. | -281.81 Million USD | 2533.866% |
| Agilent Technologies, Inc. | 1.35 Billion USD | -408.074% |
| OPKO Health, Inc. | -157.02 Million USD | 4468.206% |
| Homology Medicines, Inc. | -48.25 Million USD | 14314.071% |
| Geron Corporation | -193.94 Million USD | 3636.588% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 2530.761% |
| Exelixis, Inc. | 170.88 Million USD | -3913.81% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 6902.741% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 12401.815% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 1431.093% |
| Zoetis Inc. | 3.06 Billion USD | -123.493% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 3058.697% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 14330.29% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | -59.234% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 17618.453% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 2039.05% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 2661.01% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -6293.43% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -1931.851% |
| Blueprint Medicines Corporation | -486.27 Million USD | 1510.513% |
| Insmed Incorporated | -709.62 Million USD | 1066.565% |
| TG Therapeutics, Inc. | 20.63 Million USD | -33142.863% |
| Incyte Corporation | 620.52 Million USD | -1005.354% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 1044.246% |